Hematopoiesis is the process of producing all components of the blood system from hematopoietic stem cells (HSCs; Naik et al., 2013; Mendelson and Frenette, 2014; Walter et al., 2015) . HSCs are quiescent, self-renewable progenitor cells that need contact with stromal cells to keep their self-renewal property (Morrison and Scadden, 2014; Schepers et al., 2015) . Once HSCs sense signals for differentiation, asymmetry division occurs and HSCs that lose contact with stromal cells are doomed to differentiate into early lineage-restricted progenitors Tamplin et al., 2015) . Many signature markers of the oligopotent progenitors have been defined, and these progenitor populations can be successfully isolated from LSKs (Lin − Sca-1 + c-Kit + cells) for further study (Kfoury et al., 2014; Riddell et al., 2014) . Flt3 (also known as Flk2) plays a critical role in lymphoid lineage specification. Multipotent progenitors (MPPs) can generate either granulocyte/monocyte progenitors (GMPs) or common lymphoid progenitors (CLPs; Kondo, 2010) . GMPs generate myeloid cells, accompanied by the loss of lymphoid potential (Iwasaki and Akashi, 2007) , whereas CLPs give rise to all lymphoid cells, coupled with the loss of myeloid potential (Adolfsson et al., 2005) . Thus, these two downstream progenitors govern the myeloid and lymphoid developmental programs independently (Iwasaki and Akashi, 2007) . However, the molecular mechanisms regulating MPP fate decisions between GMPs and CLPs remain largely unknown.
Insulin, as the primary anabolic hormone, modulates a variety of physiological processes, including growth, differentiation, apoptosis, and synthesis and breakdown of lipid, protein, and glucose (Samuel and Shulman, 2012) . Insulin binds to its insulin receptor (InsR) to activate the receptor intrinsic tyrosine kinase, leading to activation of the PI3K-Akt pathway (Taguchi and White, 2008; Hers et al., 2011) . Insulin signaling is indispensable for glucose metabolism in cells of the muscle and adipose tissues (Taguchi and White, 2008; Bogan, 2012) . A previous study reported that insulin signaling in Drosophila melanogaster controls the maintenance of hematopoietic progenitors (Shim et al., 2012) . Suppression of insulin signaling leads to skewing differentiation of progenitor cells to myeloid cells (Shim et al., 2012) . It has been reported that diabetic patients display increased numbers of leukocytes, but decreased numbers of lymphocytes (Otton et al., 2004) . Moreover, due to immune dysfunction, diabetic patients are susceptible to microbial infection (Cani et al., 2007; Khan et al., 2014) . However, how the insulin signaling regulates the HSC fate decision in mammalian hematopoiesis is still elusive.
Accumulating evidence has shown that transcriptional regulation plays a critical role in differentiation commitment of HSCs into consequent early MPPs (Iwasaki and Akashi, 2007; Rossi et al., 2012) . Before lineage-specific genes are fully expressed, chromatins of progenitors must be maintained in a wide-open state that could be accessible for transcription machinery (Akashi et al., 2003; Iwasaki and Akashi, 2007) . Several transcription factors have been involved in the fate determination of MPPs to the following progenitors, such as GMPs and CLPs (Uhmann et al., 2007; Laurenti et al., 2013;  The lineage commitment of HSCs generates balanced myeloid and lymphoid populations in hematopoiesis. However, the underlying mechanisms that control this process remain largely unknown. Here, we show that insulin-insulin receptor (InsR) signaling is required for lineage commitment of multipotent progenitors (MPPs). Deletion of Insr in murine bone marrow causes skewed differentiation of MPPs to myeloid cells. mTOR acts as a downstream effector that modulates MPP differentiation. mTOR activates Stat3 by phosphorylation at serine 727 under insulin stimulation, which binds to the promoter of Ikaros, leading to its transcription priming. Our findings reveal that the insulin-InsR signaling drives MPP differentiation into lymphoid lineages in early lymphopoiesis, which is essential for maintaining a balanced immune system for an individual organism.
Insulin signaling controls MPP differentiation | Xia et al. 2306 Will et al., 2013) . The Ikaros family of transcription factors, characterized by their zinc finger domains, is composed of Ikaros, Aiolos, Helios, Eos, and Pegasus proteins (Georgopoulos, 2002) . Ikaros is highly expressed in the lymphoid-related subset. Ikaros-deficient mice have severe defects in the formation of fetal and adult lymphocytes (Urban and Winandy, 2004; Yoshida et al., 2006) . Of note, the cell number of myeloid cells is increased in Ikaros knockout mice (Iwasaki and Akashi, 2007) , suggesting that Ikaros plays a central role in the hematopoietic lineage decision. It has been reported that Stat3 plays a pivotal role in the maintenance of pluripotency of embryonic stem cells and self-renewal of HSCs (Raz et al., 1999; Chung et al., 2006) . A recent study showed that mice with Stat3 conditional deletion in the hematopoietic system display a shifted lymphoid/myeloid ratio (Mantel et al., 2012) , suggesting that Stat3 may also be implicated in hematopoietic lineage specification. Here, we show that InsR is constitutively expressed in multipotent hematopoietic progenitors. Insr deficiency leads to differentiation of MPPs into myeloid cells accompanied by reduced lymphoid cells. The insulinInsR signaling is required for lymphoid lineage specification in early lymphopoiesis.
RES ULTS Insr knockout mice increase myeloid cells but decrease lymphoid cells
To explore the role of insulin signaling in hematopoiesis, we first checked expression levels of InsR in the hematopoietic system. InsR was constitutively expressed in all the hematopoietic progenitors and had a higher expression level in MPPs than other populations ( Fig. 1 A and Fig. S1 A) . The expression levels of InsR in LSKs were further validated by confocal microscopy ( Fig. 1 B) . We then generated MxCre (Brüning et al., 1998) . After injecting poly(I:C) three times in 5 d to induce expression of the Cre recombinase, Insr was deleted thoroughly in the BM of Insr conditional knockout mice (Fig. 1 C; (Fig. 1 D) , with expansion of spaces between lymphoid follicles (Fig. 1 E) . Moreover, Insr −/− spleens had an expansion of myeloid cells but a reduction of lymphoid cells (Fig. 1 F) . The skewing myeloid/lymphoid ratio was also observed in BM examined by flow cytometry using markers for myeloid cells (Fig. 1 G) and lymphoid cells (Fig. 1 H) .
Dynamic analysis of BM cells showed that myeloid cells in BM increased gradually after Insr deletion (Fig. 1 I) , accompanied by declined lymphoid cells (Fig. 1 J) . Moreover, mature cells positive for specific myeloid markers were significantly increased (Fig. 1 K) , whereas B cells were markedly decreased in Insr KO mice (Fig. 1 K) . When we checked peripheral blood compositions, we found that myeloid-derived cells were dramatically increased, but lymphoid-derived cells were decreased (Table 1 and Fig. 1 L) . Additionally, absolute numbers of lymphoid cells were markedly declined in Insr KO BM 16 wk after Insr deletion (Fig. 1 M) . Collectively, these results indicate that Insr deficiency increases myeloid cells but reduces lymphoid cells.
Insr-deficient LSKs tend to differentiate into myeloid cells but not lymphoid cells
We stained Insr +/+ and Insr −/− BM cells with several cellular surface markers that could distinguish between self-renewable stem cells and differentiated progenitor cells ( Fig. 2 A and Fig.  S1 B) . As expected, progenitors for granulocyte/monocyte progenitors (GMPs) were remarkably increased in Insr −/− BM cells (Fig. 2 B) , whereas CLPs were decreased. However, cell numbers of self-renewable hematopoietic stem cells (HSCs) and MPPs in the LSK population were unchanged after Insr deletion (Fig. 2 B) . We then intraperitoneally injected BrdU (7.5 mg/kg) into Insr +/+ and Insr −/− mice for 18 h, and then examined BrdU incorporation in isolated GMPs and CLPs. We found the percentages of BrdU-positive cells were comparable between Insr +/+ and Insr −/− cells (Fig. 2 C) . Moreover, the S/G2/M state was also comparable between Insr +/+ and Insr −/− cells through cell cycle analysis with Hoechst 33342 and pyronin Y staining (Fig. 2 D) . Finally, we checked the activation state of caspase-3, an early marker of apoptosis. We found that the apoptotic cells were comparable between Insr +/+ and Insr −/− cells (Fig. 2 E) . These results suggest that the shifted ratio of the GMPs and CLPs might be caused by differentiation commitment of the LSK population.
Self-renewal is essential for HSCs to maintain their population long term, and altered self-renewal activity can affect the numbers of downstream populations (Riddell et al., 2014; Tamplin et al., 2015) . To test whether the self-renewal property was changed in Insr −/− LSK cells, we used a long-term culture initiating cell (LT-CIC) assay to detect the long-term self-renewal ability of Insr deficient cells. Consistent with the unchanged composition of LSKs determined by flow cytometry, percentages of colony-forming cells (CFCs) were comparable between Insr −/− and Insr +/+ LSKs (Fig. 2 F) , indicating that the skewed myeloid/lymphoid ratio in Insr −/− mice was not caused by abnormality in self-renewal of LSKs. Moreover, when we sequentially transplanted Insr +/+ and Insr −/− LSKs into recipient mice, similar numbers of reconstituted LSKs were observed (Fig. 2 G) , suggesting that the self-renewal capacity of LSKs was not affected by Insr deletion. We then used an in vitro assay to test the differentiation potential of Insr −/− LSKs. Insr −/− LSKs exhibited enhanced differentiation potential to myeloid cells in CFC assays (Fig. 2 H) , but decreased lymphoid differentiation potential when co-cultured with OP9 cells (Fig. 2 I) . However, the differentiation potential toward erythrocytes was not changed after Insr depletion (Fig. 2 J) . These data suggest that Insr deletion biases LSKs to differentiate into myeloid cells.
To further verify that the biased differentiation potential of Insr −/− LSKs was intrinsic, we transplanted BM cells Insr was examined in sorted cell populations through RT-PCR. mRNA levels were first standardized to β-actin, and are shown relative to that of muscle cells. (B) The indicated cells were stained with anti-InsR antibody (green) and counterstained with propidium iodide (PI; red) for nuclei, followed by confocal microscopy. (Fig. 2 K) . Subsequently, neutrophils were significantly increased, whereas lymphocytes were decreased in the peripheral blood of MxCre + ;Insr flox/flox LSK-reconstituted mice (unpublished data). Moreover, in competitive transplantation experiments, in which 100 Insr −/− LT-HSC cells and 3 × 10 5 CD45.1 BM cells were together transplanted into lethally irradiated CD45.1 mice, the skewed myeloid/lymphoid ratio was still observed (Fig. 2 L) . Collectively, our results suggest that Insr-deficient LSKs tend to differentiate into myeloid cells but not lymphoid cells.
Insulin-InsR signaling governs differentiation of LSKs into lymphoid cells
We next wanted to determine whether insulin could regulate LSK differentiation through InsR engagement. We in vitro cultured isolated LSKs with or without insulin. We found that insulin stimulation could cause InsR activation in LSKs (Fig. 3 A) . After being cultured in CFC-assay medium for 10 d, MPPs pretreated with insulin had a declined myeloid colony number, whereas cells pretreated without insulin had an increased myeloid colony number (Fig. 3 B) . However, insulin challenge had no effect on the differentiation potential of Flk2 − LSKs (Fig. 3 B) . In contrast, when co-cultured with OP9 for lymphoid differentiation, MPPs pretreated with insulin had more lymphoid cells, whereas MPPs without insulin had fewer lymphoid cells (Fig. 3 C) . In addition, insulin incubation did not cause the changes of cell cycle state and apoptotic cell rate in Flk2 − LSKs and MPP cells (Fig. 3, D and E) . To further determine the physiological role of insulin signal in MPP differentiation, we injected insulin in mice to elevate insulin levels. Importantly, we found that insulin injection caused significantly decreased myeloid progenitor cells (Fig. 3 F) , while dramatically increasing lymphoid cells in the BM.
To more clearly delineate the effect of insulin on LSKs in vivo, we monitored the insulin levels of mice during one feeding cycle (Casanova-Acebes et al., 2013) . The insulin level was higher at the end of the night (8:00 am), while it was lower at the end of the day (8:00 pm; unpublished data). Consequently, there were more lymphoid cells but fewer myeloid cells at the end of the night compared with those of the day (unpublished data). When mice were starved to decline their circulating insulin levels, we found that starvation-treated mice had more myeloid cells but fewer lymphoid cells than those of control-treated mice (unpublished data), suggesting that the insulin-InsR signaling might be required for the fate decisions of LSKs.
To further determine whether insulin-InsR signaling indeed directs differentiation of LSKs, Insr −/− LSKs rescued with InsR were transplanted into lethally irradiated CD45.1-recipient mice (Fig. 3 G) . After successfully reconstitution of the recipient BM, mice were injected with insulin to elevate the circulating insulin level. Only mice reconstituted with InsR could rescue Insr −/− LSKs for differentiation with insulin stimulation (Fig. 3 H) , which was similar to WT LSKs. These data suggest that insulin-InsR signaling affects the fate decision of LSKs. We generated diabetic mice that impaired insulin production (Yan et al., 2015; Fig. 3, I and J) . More importantly, these mice had more GMPs but fewer CLPs than those of control mice (Fig. 3 K) . Finally, proliferation and apoptosis states of GMPs and CLPs displayed no difference in diabetic mice and WT control mice (Fig. 3 , L and M). Notably, IGF1R, the other insulin-binding receptor, was almost undetectable in MPPs (unpublished data). Altogether, the insulin-InsR signaling governs the differentiation of LSKs into lymphoid cell lineages.
It has been reported that HSCs are heterogeneous with myeloid-biased progenitors in CD150 high CD34
− LSKs (Morita et al., 2010) . To test whether the insulin signaling − LSKs (Fig. 4, A − LSKs promoted myeloid commitment (Fig. 4 , C and D), but declined lymphoid differentiation potential. In addition, the overall donor chimerism between these cell populations was similar (Fig. 4, E (Fig. 4 J) . In sum, these data suggest that the insulin signaling is involved in the skewing myeloid/lymphoid differentiation of MPPs, but not in the myeloid-biased HSCs.
Insulin-InsR signaling controls differentiation of LSKs through modulation of Ikaros expression
Lymphopoiesis requires lineage-specific signature genes, such as Ikaros, IL-7R, Lck, and Ly-6D (Akashi et al., 2003; Nodland et al., 2011; Brownlie and Zamoyska, 2013) , to direct restricted lineage differentiation. We checked whether insulin initiates expression of these lymphoid signature genes for lymphoid differentiation. Through analyzing enrichment/depletion of lineage signatures (Akashi et al., 2003) , we found that lymphoid-related genes tended to be down-regulated, whereas myeloid-related genes were up-regulated in Insr ST-HSCs compared with Insr +/+ counterpart populations. Ikaros has been defined as critical for lymphoid differentiation (Iwasaki and Akashi, 2007) . Therefore, we focused on the modulation of Ikaros in lymphopoiesis for insulin-InsR signaling. We first examined expression of Ikaros in the BM. Ikaros exhibited the highest expression level in CLPs and a modest level in MPPs (Fig. 5 C) , which was consistent with previous reports (Yoshida et al., 2006; Iwasaki and Akashi, 2007) . Interestingly, Insr knockout only affected the expression level of Ikaros in MPPs (Fig. 5 C) , but remained unchanged in other hematopoietic progenitors.
We then determined Ikaros expression in MPPs under insulin stimulation. We found that insulin promoted the expression of Ikaros in MPPs (Fig. 5 C) , but not in LT-HSCs or ST-HSCs. Additionally, Insr deficiency could not activate Ikaros expression in MPPs (Fig. 5 C) . In parallel, starved mice with a low level of insulin showed reduced expression of Ikaros, and refeeding mice exhibited elevated expression of Ikaros (Fig. 5 D) . Moreover, Ikaros was remarkably decreased in MPPs in the starved mice (Fig. 5 E) , which was in agreement with the lower insulin level (not depicted). Finally, we found that insulin incubation could promote Ikaros expression in all MPP cells we examined, but not in Flk2 − LSKs (Fig. 5 F) , further validating a restrictive effect of insulin signaling on the Ikaros expression in MPPs.
To further explore the role of Ikaros in the fate decision of MPPs, we reconstituted lethally irradiated mice with either Ikaros-silenced or -overexpressed MPPs. Expectedly, Ikaros knockdown drove MPPs to differentiate into myeloid cells (Fig. 5, G and H) , whereas Ikaros overexpression in MPPs led to more lymphoid cells (Fig. 5, I and J), suggesting that Ikaros activation was indispensable for the lymphoid differentiation of MPPs. To further determine the relationship between InsR and Ikaros, we introduced Ikaros to Insr −/− MPPs for rescue experiments (Fig. 5 K) . Importantly, Insr −/− MPPs with Ikaros restoration generated fewer myeloid colonies than empty vector-treated Insr −/− MPPs (Fig. 5 L) . However, Insr −/− MPPs with Ikaros restoration produced many more lymphoid cells (Fig. 5 M) . Additionally, Ikaros restoration was able to rescue colony numbers of Insr −/− MPPs to similar levels with those of Insr +/+ MPPs either in a CFC assay or in an OP9 co-culture system (Fig. 5, L and M) . These data suggest that Ikaros acts downstream of insulin-InsR signaling to control the fate decision of MPPs.
Insulin-InsR signaling enhances Ikaros expression in MPPs through activation of mTOR
The mechanistic target of rapamycin (mTOR) is a serine/ threonine protein kinase that acts as a master regulator of cellular growth and metabolism in response to nutrient and hormonal regulation (Laplante and Sabatini, 2012; Johnson et al., 2013) . mTOR was a key regulator downstream of the insulin-InsR signaling pathway (Chi, 2012; Inoki et al., 2012; Powell et al., 2012) . To examine whether mTOR is involved in regulation of the expression of Ikaros, we overexpressed mTOR in MPPs and checked the expression level of Ikaros. Interestingly, we found that mTOR overexpression in MPPs dramatically increased the expression level of Ikaros upon insulin stimulation (Fig. 6, A and B) . However, without insulin .1 BM cells into lethally irradiated CD45.1 mice, followed by progenitor cell examination in reconstituted BM 8 wk later. n = 8 per strain. Data are shown as means ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Data represent at least three separate experiments. (Fig. 6 C) . We observed that mTOR knockdown remarkably reduced Ikaros expression in MPPs, which was comparable to that of shCtrl MPPs, even with insulin stimulation (Fig. 6 D) . These data indicate that insulin-InsR signaling-mediated mTOR activation participates in the transcriptional activation of Ikaros in MPPs. mTOR functions in two different complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2; Lamming et al., 2012; Bar-Peled et al., 2013) . Rapamycin inhibits mTORC1 from suppressing mTOR activity (Yip et al., 2010) . Importantly, rapamycin addition could inhibit Ikaros expression in MPPs with insulin stimulation (Fig. 6 E) , suggesting that mTORC1 is involved in the expression of Ikaros in MPPs. Moreover, through RT-PCR analysis, mTOR dramatically promoted Ikaros expression (Fig. 6 F) , whereas the kinase-dead mTOR mutant (mTOR-KD) had no such activity. These observations verify that mTOR is indeed involved in the transcriptional activation of Ikaros in MPPs. We next determined the effect of rapamycin on MPP differentiation using an in vitro differentiation assay. As expected, MPPs pretreated with rapamycin produced more myeloid cells than vehicle-treated cells ( Fig. 6 G) ; however, rapamycin pretreatment significantly decreased the numbers of lymphoid cells (Fig. 6 H) . A reversible inhibitor of PI3Ks, LY294002, acts as an upstream inhibitor of mTOR . LY294002 could also drive MPPs to myeloid cell differentiation (Fig. 6,  I and J). We transplanted shCtrl or mTOR-silenced MPPs into normal or diabetic mice to determine whether mTOR acted downstream of insulin signaling. Intriguingly, we observed that mTOR-silenced MPPs were prone to differentiate into myeloid cells in normal mice (Fig. 6 K) . In contrast, this trend did not appear in insulin-suppressed diabetic mice, whose mice had more myeloid cells and fewer lymphoid cells compared with normal mice. In sum, these results suggest that mTOR enhances Ikaros expression that acts downstream of the insulin-InsR signaling in lymphopoiesis.
Stat3 acts as a downstream regulator of insulin-InsR-mTOR signaling to initiate the transcription of Ikaros
To identify the transcription factors that are responsible for Ikaros transcription downstream of insulin-InsR-mTOR signaling in MPPs, we silenced several transcription factors that were known to be regulated by mTOR (Chi, 2012; Powell et al., 2012) . Surprisingly, among several factors we checked, only Stat3 knockdown abolished the enhanced expression of Ikaros after insulin stimulation (Fig. 7 A) , which was comparable to that of shCtrl-treated cells. Importantly, Stat3 associated with the promoter of Ikaros in MPPs upon insulin stimulation through chromatin immunoprecipitation (ChIP) assays (Fig. 7 B) . Moreover, Stat3 could vigorously activate Ikaros expression with insulin administration (Fig. 7, C  and D) . To further determine the physiological role of Stat3 in Ikaros expression, we generated Stat3 conditional knockout mice in the hematopoietic system. Stat3 was completely deleted in the BM (Fig. 7 E) . More importantly, Stat3 deletion impaired the expression of Ikaros upon insulin stimulation (Fig. 7 F) . These data suggest that Stat3 binds to the promoter of Ikaros to initiate its expression with insulin stimulation.
Stat3 is activated by a variety of cytokines and growth factors (Casanova et al., 2012) . Stat3 is phosphorylated at its two key residues, Tyr705 and Ser727. Ser727 phosphorylation is involved in the modulation of Stat3 activity, whereas Tyr705 phosphorylation participates in its dimerization and activation (Wen et al., 1995; Calò et al., 2003) . To determine whether mTOR activates Stat3 upon insulin stimulation in MPPs, we performed immunoblotting with MPP cell lysates obtained from different treatments. Interestingly, we observed that Stat3 was phosphorylated at serine 727 (S727; Fig. 7 G) , instead of the canonical site tyrosine 705 (Y705), with insulin stimulation in MPPs. More importantly, rapamycin completely blocked S727 phosphorylation (Fig. 7 G) . These data suggest that mTOR acts as an upstream factor to activate Stat3 by its phosphorylation. Furthermore, the serine 727 to alanine mutation (S727A) of Stat3 failed to augment the activation of Ikaros (Fig. 7, H and I) , whereas the Y705F Stat3 mutant still augmented Ikaros activation. Additionally, rapamycin addition completely abolished the activation of Ikaros, even when cotransfected with WT Stat3 (Fig. 7 I) . Importantly, we observed that Stat3 translocated from the cytoplasm to the nucleus upon insulin stimulation (Fig. 7 J) , whereas rapamycin impaired this activity. These results suggest that Stat3 is activated by mTOR with insulin signaling to initiate the transcription of Ikaros.
We found that Stat3 deficiency reduced Ikaros expression upon insulin stimulation (Fig. 7 F) . We next detected the differentiation potential of Stat3 −/− MPPs. Stat3 −/− MPPs produced many more myeloid cells compared with those of WT Stat3 +/+ cells (Fig. 7 K) . In contrast, Stat3 −/− MPPs generated fewer lymphoid cells (Fig. 7 L) . We then transplanted Stat3 −/− or Stat3 +/+ MPPs into normal or diabetic mice to determine whether Stat3 is the transcription factor downstream of the insulin-InsR signaling. Importantly, we found that Stat3 −/− MPPs generated more myeloid cells in normal mice (Fig. 7 M) , whereas fewer lymphoid cells. However, in diabetic mice, Stat3
−/− MPPs exhibited no such difference. Together, these results indicate that Stat3 acts downstream of insulin-InsR-mTOR signaling to activate the expression of Ikaros in MPPs, leading to lymphoid lineage specification.
DIS CUSSI ON
The lineage commitment of HSCs results in distinct myeloid and lymphoid differentiation pathways, leading to the generation of common myeloid progenitors and CLPs (Iwasaki and Akashi, 2007; Rossi et al., 2012) . However, the underlying mechanisms that modulate the lineage specification properties of early progenitors have not been defined yet. In this study, we show that InsR is constitutively expressed in multipotent hematopoietic progenitors. Deletion of InsR in murine BM causes biased differentiation of MPPs toward myeloid cells. Insulin-InsR signaling initiates the expression of Ikaros, which is required for lymphoid differentiation. Without insulin signaling, Ikaros expression is suppressed and MPPs are prone to differentiate into myeloid cells. mTOR acts as a downstream effector that modulates MPP differentiation specification. mTOR activates Stat3 by phosphorylation at serine 727 under insulin stimulation, which translocates to the nucleus of MPPs to bind to the promoter of Ikaros, leading to its transcription priming. Our findings demonstrate that insulin-InsR signaling plays a critical role in governing MPPs toward lymphoid lineages in early lymphopoiesis.
HSCs have an open chromatin structure that allows the transcription of many genes, most of which are myeloid-related (Akashi et al., 2003; Laurenti et al., 2013) . Lymphoid-related genes come later during the lineage specification process (Akashi et al., 2003) . It is therefore suggested that HSCs are prone to differentiate into myeloid cells and extrinsic signals are required for priming lymphoid lineage + cells were calculated at the indicated intervals. Bar, 2 µm. Data are shown as means ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Data are representative of three independent experiments. JEM Vol. 212, No. 13 commitment. HSCs differentiate to lymphoid-primed MPPs, then to lymphoid-restricted progenitors, accompanied by the loss of erythroid-megakaryocyte and myeloid potential (Adolfsson et al., 2005) . More recently, many studies reported the lineage-instructive capacities of several cytokines on hematopoietic stem/progenitor cells. For example, M-CSF directly induces expression of the myeloid master regulator PU.1 to direct myeloid cell-fate specification in mouse HSCs (Mossadegh-Keller et al., 2013) . Erythropoietin (Epo) triggers erythroid lineage skewing at all lineage bifurcations between HSCs and erythroid progenitors (Grover et al., 2014) . Here, we show that InsR is constitutively expressed in the multipotent hematopoietic progenitors of BM and that extrinsic insulin signaling is required for lymphoid lineage specification in early lymphopoiesis. Notably, we obtained quite high counts of peripheral white blood cells in Insr +/+ and Insr −/− mice, which might be caused by a sensitive blood cell counter we used. In reality, Insr-deficient mice displayed much higher peripheral white blood cell counts than WT mice. Our study also demonstrates that insulin-suppressed diabetic mice have more myeloid cells and fewer lymphoid cells compared with normal WT mice. A recent study showed that high fat dietinduced obesity produces skewed myeloid progenitors that potentiate generation of macrophages (Singer et al., 2014) , augmenting inflammatory responses in metabolic tissues. Interestingly, prolonged fasting can reduce circulating IGF-1 levels in LT-HSCs and niche cells, which promote self-renewal, and lineage-balanced regeneration of HSCs (Cheng et al., 2014) . Of note, Ding and Morrison (2013) reported that lymphoid/myeloid-skewed HSCs occupy distinct BM niches (Oguro et al., 2013) , suggesting that a specialized microenvironment in which progenitors reside also plays a critical role in hematopoiesis.
The membrane InsR binds to insulin to turn on the PI3K-Akt pathway (Fruman and Rommel, 2014) . Akt can phosphorylate to activate mTOR, which is present in two distinct protein complexes: mTORC1 and mTORC2 (Shimobayashi and Hall, 2014) . mTORC1 phosphorylates its main effector substrates, eukaryotic translation initiation factor 4E (eIF-4E)-binding protein 1 (4E-BP1) and 70-kD ribosomal S6 protein kinase (S6K), to potentiate protein translation and synthesis. Besides its role in metabolism, mTORC1 is also involved in mitochondrial biosynthesis and autophagy (Cunningham et al., 2007; Yu et al., 2010) . Rapamycin binds to FKBP12 by binding to the FRB site on mTOR, which blocks the ability of Raptor to bind to mTOR to inhibit the activity of mTORC1 (Powell et al., 2012) . Prolonged treatment with rapamycin for some tissues and cells are able to suppress the mTORC2 activity as well (Sarbassov et al., 2006) . In this study, we found that mTOR phosphorylates Stat3 at serine 727, a novel substrate for mTOR, which is indispensable for the transcriptional activation of Ikaros in MPPs. Both mTOR knockdown and rapamycin treatment are able to suppress the expression of Ikaros in MPPs. How mTORC1 and mTORC2 function in early lymphopoiesis remains to be further investigated.
Ikaros plays an essential role in the modulation of lymphoid development and differentiation (Iwasaki and Akashi, 2007) . Neonatal Ikaros-null mice appear to be a complete defect in fetal thymocyte development. Adult Ikaros-deficient mice block lymphoid differentiation and exhibit thymocyte development skewed to CD4 T cells (Urban and Winandy, 2004) . Interestingly, the numbers of myeloid cells are increased in Ikaros deficient mice. In mature CD4 + T cells, Ikaros modulates a variety of processes including Th2 differentiation and cytokine production (Bandyopadhyay et al., 2007; Quirion et al., 2009) . In B cells, the transcription factor FoxO1 plays a critical role in Ikaros expression, whereas FoxO1 does not directly initiate Ikaros transcription. However, the transcriptional activation of Ikaros is poorly understood in hematopoietic lineage specification. Here, we show that InsR is highly expressed in hematopoietic progenitors, with the highest level in MPPs. Extrinsic insulin-InsR signaling directly activates Stat3 in MPPs to initiate Ikaros transcription.
Stat3 is well known to maintain the pluripotency of embryonic stem cells under the control of LIF signaling (Yu et al., 2014) . Stat3 also participates in sustaining HSC self-renewal (Chung et al., 2006) . Mice with Stat3 conditional deletion in the hematopoietic system display increased numbers of myeloid cells and decreased numbers of lymphoid cells, a phenomenon similar to ageing mice (Mantel et al., 2012) . Reactive oxygen species (ROS) levels are elevated in HSCs and hematopoietic progenitor cells. Lymphopoietic activity becomes compromised during ageing (Montecino-Rodriguez and Dorshkind, 2006) . The earliest lymphoid progenitor pools are declined in aged BM (Miller and Allman, 2005) . Senescence may decrease the sensing ability to insulin signaling due to insulin resistance. Disrupted insulin secretion in mouse diabetes models generates more myeloid cells but fewer lymphoid cells, resulting in a skewed myeloid/lymphoid ratio in diabetic mice. It remains to be delineated whether insulin resistance decreases lymphoid lineage differentiation in diabetic patients, which may result in damage of the immune system and increased susceptibility to infections. We expect that our findings will provide useful clues for translational study for diabetic patients. In summary, our observations reveal that insulin-InsR signaling drives MPP differentiation into lymphoid lineages in early lymphopoiesis, which is essential for maintaining a balanced immune system for an individual organism.
MAT ERIALS AND MET HODS Antibodies and reagents.
The following commercial antibodies were used: mouse hematopoietic lineage eFlour 450 cocktail, PerCP-Cy5.5-anti-CD45.1, FITC-anti-CD45.2, Alexa Fluor 700-anti-IL-7Rα, FITC-anti-Ly6A/E (Sca-1), PE-anti-CD117 (c-Kit), APC-eFluor780-anti-CD48, anti-CD3, anti-CD19, FITC-anti-CD11b, PE-anti-Gr1, FITC-anti-B220, Pecy5-anti-CD3ε, APC-anti-Flt3/CD135, anti-F4/80, anti-Gr-1, and anti-CD34 were purchased from eBioscience. PE-cy7-anti-CD150 was obtained from BioLegend. PerCP-Cy5.5-conjugated goat anti-rat IgG and APC-Cy7-conjugated goat anti-rabbit IgG were purchased from Santa Cruz Biotechnology, Inc. Anti-β-actin was from Sigma-Aldrich. Antibodies against Insr-β, phosphorylated Insr-β (Tyr1150/1151), insulin, mTOR, Stat3, S727 phosphorylated Stat3, Y705 phosphorylated Stat3, S6K, and phosphorylated S6K were purchased from Cell Signaling Technology. Donkey anti-rabbit or anti-mouse secondary antibodies conjugated with Alexa Fluor 488, 594, or 405 were purchased from Molecular Probes. HRP-conjugated secondary antibody was obtained from Santa Cruz Biotechnology, Inc. Propidium iodide (PI), Annexin-V, insulin, rapamycin, and streptozotocin (STZ) were purchased from Sigma-Aldrich.
Cell culture. For HSC or MPP culture, cells were cultured in StemPro-34 medium (Invitrogen), containing 4 mM l-glutamine, 100 µg/ml streptomycin, 100 U/ml penicillin, and the following cytokines (all from PeproTech): 10 ng/ml IL-3, 25 ng/ml SCF, 25 ng/ml Ftl-3L, 10 ng/ml GM-CSF, 25 ng/ml IL-11, 4 U/ml Epo, and 25 ng/ml Tpo. 
